Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company with an active flow of corporate, clinical, and financial news. The company develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses, and its communications frequently highlight progress in these areas. Investors following ANIP news can track how the Rare Disease segment, including products such as ILUVIEN and Purified Cortrophin Gel, contributes to the company’s growth alongside its generics and branded drug portfolios.
News updates for ANI often cover financial results and guidance, including quarterly earnings releases, adjusted non-GAAP metrics, and full-year outlooks. Press releases and related Form 8-K filings provide detail on net revenues by segment, the performance of key products, and management’s commentary on business trends. These disclosures also outline how Rare Disease revenues, particularly from Cortrophin Gel and ILUVIEN, compare with contributions from Generics and Brands.
ANIP news also includes clinical and medical developments, such as results from the NEW DAY clinical trial of ILUVIEN in diabetic macular edema and their presentation at major ophthalmology and retina meetings. The company reports on initiatives like the FutureVision Advisory Council, a group of retina and uveitis specialists formed to help guide its ophthalmology and retina franchise. Updates on Phase 4 trials, label transitions, and adoption trends for ILUVIEN and related products are also featured.
In addition, ANI regularly announces corporate and governance updates, including board transitions and leadership roles, as well as participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Jefferies, H.C. Wainwright, and Morgan Stanley. These events often involve presentations or fireside chats where management discusses strategy, the transformation toward a rare disease–focused profile, and capital allocation priorities.
By monitoring ANIP news, readers can follow developments across rare disease therapeutics, generics, branded products, clinical research, and capital markets activity, all of which shape the company’s trajectory.
ANI Pharmaceuticals, Inc. announced the FTC's acceptance of the proposed consent order regarding its acquisition of Novitium Pharma. The FTC requires the divestiture of development rights to one generic drug and related assets of another, deemed immaterial to ANI's business. With this decision, ANI has cleared the necessary antitrust hurdles, proceeding to close the acquisition around November 18, 2021, subject to customary conditions. This acquisition is strategic, aiming to enhance ANI's portfolio in the pharmaceutical market.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) has successfully completed its underwritten public offering, selling 1,500,000 shares at $50.00 each, generating gross proceeds of $75 million. Underwriters have a 30-day option to buy an additional 225,000 shares. Guggenheim Securities and Raymond James served as book-running managers. The offering was made under a shelf registration statement filed with the SEC. ANI focuses on developing high-quality branded and generic pharmaceuticals, particularly in niche areas such as oncology and controlled substances.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced a public offering of 1,500,000 shares of common stock priced at $50.00 per share, aiming to raise $75 million in gross proceeds. Underwriters have a 30-day option to buy an additional 225,000 shares. The offering is expected to close around November 8, 2021, pending customary conditions. The offering is made under a shelf registration statement filed with the SEC. Guggenheim Securities leads the offering, with additional involvement from Raymond James and H.C. Wainwright & Co.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced an underwritten public offering of its common stock, subject to market conditions. The company intends to use the net proceeds for Cortrophin commercialization efforts, including sales and marketing, and for general corporate purposes, which may include acquiring or investing in additional businesses and technologies. Guggenheim Securities is acting as the book-running manager. The offering is part of a shelf registration statement with the SEC effective since July 17, 2020.
ANI Pharmaceuticals reported Q3 2021 net revenues of $52.1 million, a slight decrease from $53.0 million in Q3 2020. The company faced a net loss of $4.4 million with a diluted loss per share of ($0.37). Adjusted non-GAAP EBITDA was $16.6 million with adjusted diluted EPS at $1.01. The FDA approved the Purified Cortrophin™ Gel for chronic autoimmune disorders, with a launch planned for Q1 2022. Additionally, the acquisition of Novitium Pharma LLC is set to close in November 2021, and the company launched Nebivolol Tablets from two sites.
ANI Pharmaceuticals announced FDA approval for Cortrophin Gel, a critical treatment for chronic autoimmune disorders such as multiple sclerosis and rheumatoid arthritis. This approval restores much-needed options for patients and physicians in the U.S. market. ANI plans a full-scale launch in early Q1 2022, following a significant investment in manufacturing. The gel offers alternatives for patients intolerant to corticosteroids, marking a pivotal return to a long-standing treatment option first approved in 1954.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced it will release its third quarter 2021 financial results on November 1, 2021, at 8:30 a.m. ET. The call will be hosted by President and CEO Nikhil Lalwani and Senior VP and CFO Stephen P. Carey. Investors can access the live webcast at www.anipharmaceuticals.com, where a replay will also be available. The company focuses on developing, manufacturing, and marketing both branded and generic pharmaceuticals, aiming for sustainable growth through various initiatives in the bio-pharmaceutical sector.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) has announced that CEO Nikhil Lalwani and CFO Stephen Carey will present at the Cantor Virtual Global Healthcare Conference on September 30, 2021, at 8:00 a.m. ET. The presentation will be available via a live webcast and archived for 30 days on the Company's website under the Investors section. ANI Pharmaceuticals is dedicated to developing, manufacturing, and marketing quality pharmaceutical products, focusing on sustainable growth through its Purified Cortrophin Gel® franchise and generics business.
ANI Pharmaceuticals has launched its generic version of Bystolic, called Nebivolol Tablets, available in 2.5 mg, 5 mg, 10 mg, and 20 mg dosages. The U.S. market for Bystolic is approximately $1.05 billion. The launch was executed simultaneously from two manufacturing sites, demonstrating ANI's supply chain capabilities. Nebivolol is prescribed for treating hypertension and can be used alone or with other medications. The company emphasizes its commitment to sustainable growth through its generics division and innovative product development.
ANI Pharmaceuticals announced that the FDA has accepted its supplemental New Drug Application for Purified Cortrophin Gel. This is a significant milestone with a target action date set for October 29, 2021. The company plans to launch this second ACTH-based treatment, which is vital for patients with chronic autoimmune disorders like multiple sclerosis and rheumatoid arthritis. ANI Pharmaceuticals aims to strengthen its market position through this new drug while continuing to enhance its generics business.